Viewing Study NCT01482156

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:24 PM
Ignite Modification Date: 2026-03-05 @ 8:01 PM
Study NCT ID: NCT01482156
Status: COMPLETED
Last Update Posted: 2020-12-21
First Post: 2011-09-26
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Solid Tumors View
None Metastatic Breast Cancer View
None Metastatic Renal Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced solid tumors View
None Metastatic renal cell carcinoma (mRCC) View
None ER+/HER2-Metastatic breast cancer (MBC) View
None Dose finding study View
None mTOR View
None Pl3K View
None BEZ235 View
None RAD001 View
None Everolimus View
None Afinitor® View
None ER+/HER2- metastatic breast cancer View